前列地尔联合依帕司他对糖尿病足患者创面肉芽组织TNF-α、IL-6、VEGF表达影响

来源期刊：广州医药 | 10-14 发布时间：2021-12-01 收稿时间：2025/11/13 17:23:09 阅读量：23

作者：: 黄余湘,

关键词：: 联合治疗糖尿病足 TNF-α IL-6 VEG; Combined therapy Diabetic foot TNF-α IL-6 VEGF

DOI：: 10.3969/j.issn.1000-8535.2018.02.003

收稿时间：: 2017-09-27
修订日期：
接收日期：
引用总数：: 0

目的探讨前列地尔联合依帕司他对糖尿病足患者创面肉芽组织肿瘤坏死因子(tumor necrosis factor-α,TNF-α)、白介素-6 (interleukin-6,IL-6)及血管内皮生长因子(vascular endothelial growth factor,VEGF)表达的影响。方法将90例糖尿病足患者随机分为研究组和对照组,每组45例,对照组予常规治疗,研究组在常规治疗基础上给予前列地尔+依帕司他联合治疗。监测两组患者创面愈合率,患肢足背血流动力学及腓总神经传导速度,创面肉芽组织TNF-α、IL-6、VEGF含量及基因表达变化。结果治疗后第2、4周研究组较对照组创面愈合率升高,差异有统计学意义(P<0.05);治疗后两组患者足背动脉血流动力学及腓总神经传导速度均有改善,而研究组疗效更明显(P<0.05);治疗后研究组患者创面肉芽组织TNF-α、IL-6含量及基因表达较对照组降低,VEGF含量及基因表达则升高(P<0.05)。结论前列地尔联合依帕司他联合治疗可改善糖尿病足患者足背动脉血流动力学,促进受损神经功能恢复;降低糖尿病足患者创面肉芽组织TNF-α、IL-6表达,减轻免疫损伤;增加VEGF基因表达,促进血管生成,加速创伤愈合。

1、 KAZMIERCZAK E, GRAJEK S, KOWAL J, et al. Prognostic usefulness of IL-6 and VEGF for the occurrence of changes in coronary arteries of patients with stable angina and implanted stents[J]. Eur Rev Med Pharmacol Sci, 2014, 18(15): 2169-2175.

2、 VEMPATI P, POPEL A S, MAC GABHANN F. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning[J]. Cytokine Growth Factor Rev, 2014, 25(1): 1-19.

3、 TANAKA T, NARAZAKI M, KISHIMOTO T. IL-6 in inflammation, immunity, and disease[J]. Cold Spring Harb Perspect Biol, 2014, 6(10): a016295.

4、 GOMEZ-HERNANDEZ A, PERDOMO L, DE LAS HE-RAS N, et al. Antagonistic effect of TNF-alpha and insulin on uncoupling protein 2 (UCP-2) expression and vascular damage[J]. Cardiovasc Diabetol, 2014,13(1):108.

5、 REDDY T N, RAVINDER M, BAGUL P, et al. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs)[J]. Eur J Med Chem, 2014, 71: 53-66.

6、 AUGUSTIN A J, DIEHM C, GRIEGER F, et al. Alprostadil infusion in patients with dry age related macular degeneration: a randomized controlled clinical trial[J]. Expert Opin Investig Drugs, 2013, 22(7): 803-812.

7、 JONES M S, RIVERA M, PUCCINELLI C L, et al. Targeted amino acid supplementation in diabetic foot wounds: pilot data and a review of the literature[J]. Surg Infect (Larchmt), 2014, 15(6): 708-712.

8、 MARGOLIS D J, HAMPTON M, HOFFSTAD O, et al. Health literacy and diabetic foot ulcer healing[J]. Wound Repair Regen, 2015, 23(3): 299-301.

9、 TABUR S, EREN M A, CELIK Y, et al. The major predictors of amputation and length of stay in diabetic patients with acute foot ulceration[J]. Wien Klin Wochenschr, 2015, 127(1-2): 45-50.

10、 LAZARO-MARTINEZ J L, ARAGON-SANCHEZ J, GA-RCIA-MORALES E. Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial[J]. Diabetes Care, 2014, 37(3): 789-795.

11、 WELEDJI E P, FOKAM P. Treatment of the diabetic foot-to amputate or not?[J]. BMC Surg, 2014, 14: 83.

12、 FEITOSA M C, CARVALHO A F, FEITOSA V C, et al. Effects of the Low-Level Laser Therapy (LLLT) in the process of healing diabetic foot ulcers[J]. Acta Cir Bras, 2015, 30(12): 852-857.

13、 MARKAKIS K, BOWLING F L, BOULTON A J. The diabetic foot in 2015: an overview[J]. Diabetes Metab Res Rev, 2016, 32 Suppl 1: 169-178.

14、 NOOR S, ZUBAIR M, AHMAD J. Diabetic foot ulcer-A review on pathophysiology, classification and microbial etiology[J]. Diabetes Metab Syndr, 2015, 9(3): 192-199.

15、 ANDREWS K L, HOUDEK M T, KIEMELE L J. Wound management of chronic diabetic foot ulcers: from the basics to regenerative medicine[J]. Prosthet Orthot Int, 2015, 39(1): 29-39.

16、 MORBACH S, MULLER E, REIKE H, et al. Diabetic foot syndrome[J]. Exp Clin Endocrinol Diabetes, 2014, 122(7): 416-424.